Clinical Trials Browser

Recruiting × Colonic Neoplasms × Cetuximab × Clear all

Colonic Neoplasms, Rectal Neoplasms

NCT07318805 2026-05-08

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

260 enrolled

BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT06835569 2026-05-06

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Phase 1 Recruiting

188 enrolled

GastrointestinalThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06447662 2026-04-20

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

Phase 1 Recruiting

330 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06640166 2025-02-12

ECLYPse

Phase 2 Recruiting

25 enrolled

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06575127 2024-08-28

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

Phase 2 Recruiting

60 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasms

NCT05022030 2024-03-07

CAPCET

Phase 2 Recruiting

150 enrolled

Gastrointestinal

Colonic Neoplasms

Clinical Trials

KANDLELIT-012

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.

ECLYPse

Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study

CAPCET